FDA delays decision on Merus' first-in-class cancer drug by 3 months

The FDA has scuttled Merus’ plans to win a speedy approval for its solid tumor drug zenocutuzumab. On the cusp of the priority review deadline, the agency has pushed back the decision date by three months to give its staff more time to assess recently submitted information.